Article
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
PloS one - 1 Jan 2013
Wang Ling-Zhi, Ramírez Jacqueline, Yeo Winnie, Chan Mei-Yi Michelle, Thuya Win-Lwin, Lau Jie-Ying Amelia, Wan Seow-Ching, Wong Andrea Li-Ann, Zee Ying-Kiat, Lim Robert, Lee Soo-Chin, Ho Paul C, Lee How-Sung, Chan Anthony, Ansher Sherry, Ratain Mark J, Goh Boon-Cher
Abstract excerpt
UNLABELLED: Belinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies. We studied the pharmacokinetics of belinostat in hepatocellular carcinoma patients to determine the main pa...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
